TransMedics Group Inc.（股票代码：TMDX）在发布2025年第一季度财报后，股价在夜盘交易中大幅上涨14.43%，引起投资者广泛关注。这家先进医疗设备公司的强劲业绩表现远超市场预期，推动了股价的显著上涨。
根据公司公布的财务报告，TransMedics Group 2025年第一季度实现营收1.4354亿美元，同比增长48.2%，远超分析师预期的1.2366亿美元。每股收益方面，公司报告调整后每股收益为0.70美元，大幅超越市场预期的0.26美元，也显著高于去年同期的0.35美元。公司本季度净收入达到2568万美元，展现了强劲的盈利能力。
这份亮眼的财报反映了TransMedics Group在器官移植技术领域的领先地位得到进一步巩固，市场对其产品的需求持续增长。分析师对该公司保持积极看法，目前平均评级为"买入"，12个月目标价中位数为112.50美元。值得注意的是，公司股价今年迄今已上涨53.7%，显示出良好的增长势头。投资者对这一出色表现做出积极反应，推动股价在夜盘交易中显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.